Authors
Latest:
Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLCThe expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.
Latest:
Metastatic Renal Cell Carcinoma With Sarcomatoid FeaturesIn this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.
Latest:
Revumenib Shows Efficacy and Safety in R/R KMT2Ar Acute LeukemiaRevumenib treatment results in durable MRD-negative remissions in pediatric and adult patients with relapsed/refractory KMT2A rearranged acute leukemia in the phase 2 Augment-101 study.
Latest:
Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRCThe panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple MyelomaInvestigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.
Latest:
Treatment Experience for a Patient With GVHDA patient with GVHD chronicles his treatment experience, and GVHD experts share thoughts on how to approach treatment.
Latest:
Managing AEs Associated With Bispecifics in RRMMClosing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.
Latest:
Primary Focal Therapy for Localized Prostate Cancer: A Review of the LiteratureFocal therapy for prostate cancer could balance undertreatment and overtreatment of localized prostate cancer for highly selected patients. Long-term oncologic outcomes are not yet available for any modality. Patients should be informed regarding currently available outcomes, the necessity of adherence to a stringent follow-up protocol, and the possible need for additional targeted therapy or future radical treatment in case of recurrence.
Latest:
Tagraxofusp in BPDCN: Practical Advice and Future Directions in CareAfter sharing key takeaways on the management of BPDCN, expert hematologist-oncologists highlight unmet needs and forecast evolutions in care.
Latest:
Roger Li, MD, Talks Future Analyses of CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBCRoger Li, MD, spoke about future trials planned for the combination of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.
Latest:
Medical World News® After Hours: Thoracic Medical Oncologist Inga Lennes, MD, MBA, MPH, on Healthy EatingDuring an After Hours segment of Medical World News®, Inga Lennes, MD, MBA, MPH, spoke about her passion for healthy cooking and how it helps her unwind after a busy week of treating patients.
Latest:
Novel Therapies May Lead to More Treatment Options in Sarcoma SubtypesCAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
Latest:
Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple MyelomaClosing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical ProgressionIn the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Latest:
Martha Ann Raymond, MA, on What Providers Should Do to Enhance Clinical Trial Participation in the COVID-19 EraThe founding executive director of the GI Cancers Alliance discussed important takeaways from a study of patient perspectives of clinical trial participation during the COVID-19 pandemic.
Latest:
Study Impact and Key TakeawaysSagar Lonial, MD, and Ellen Marin, PA-C, discuss the impact and key takeaways from their study as well as study limitations and future directions.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Catherine A. Shu, MD, Reviews Findings of Cohort A of the Phase 1 CHRYSALIS-2 Trial in Pretreated EGFR+ NSCLCCatherine A. Shu, MD, spoke about the most important findings from the phase 1 CHRYSALIS-2 trial for patients with previously treated EGFR-mutant non–small cell lung cancer who are administered amivantamab plus lazertinib.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Early Access to Electronic Health Records May Influence the Patient ExperienceIn a recent Hot Topics column, Mehmet Sitki Copur, MD, FACP, et al discussed the pros and cons of patients receiving test results early through electronic medical records.
